---
title: Benzodiazepine (and Barbiturate) Comparison
authors:
  - author: 'Curtis Geier, PharmD'
categories:
  - Pharmacology
  - Toxicology
created: 2020/01/15
updated: ''
---
![BenzodiazepineBarbiturateComparisonTable] (/media/Benzodiazepine-Barbiturate-Comparison-Table.png)

## Clinical Implications \[2, 10]

* All benzodiazepines and barbiturates are **metabolized by the liver**.

  * <span class="drug">Chlordiazepoxide</span>, <span class="drug">diazepam</span>, <span class="drug">midazolam</span>, <span class ="drug">phenobarbital</span>:

    > Phase I metabolism (CYP450 system): Prolonged half-lives and durations of effect with hepatic dysfunction
  * <span class="drug">Lorazepam</span>:

    > Phase II metabolism (glucuronidation): Less effect on pharmacokinetics with hepatic dysfunction.

## Pharmacokinetics \[1, 3-5, 10]

* Benzodiazepines exert primary action in central nervous system
* Drug permeability across the blood brain barrier influenced by the lipophilicity of molecule

  * A more lipophilic benzodiazepine will have a quicker onset once in **systemic circulation**.

    * IV speed of onset: <span class="drug">Diazepam</span> (fastest) > <span class="drug">lorazepam</span> (medium speed) > midazolam (slowest onset)
  * A more lipophilic benzodiazepine is more slowly absorbed following **intramuscular administration**, affecting the onset of action.

    * IM speed of onset: <span class="drug">Midazolam</span> (fastest) > <span class="drug">lorazepam</span>  (medium speed)
    * <span class="drug">Diazepam</span> onset is variable because of unreliable IM absorption
  * A more lipophilic compound quickly diffuses out of the CNS and into lipid tissue, leading to short duration of action

    * <span class="drug">Diazepam</span> has a short duration of action with a single dose despite its long T<sub>1/2</sub>. 
    * With repeated dosing the concentration will accumulate saturating the lipid tissue and protein binding, resulting in a longer effect duration approaching the T<sub>1/2</sub>.

## References

1. Greenblatt DJ, Arendt RM, Abernethy DR et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. *Br J Anaesth*. 1983 Oct;55(10):985-9. PMID [6626413](https://www.ncbi.nlm.nih.gov/pubmed/?term=6626413)
2. Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Thirteenth ed. New York: McGraw Hill Medical; 2018.
3. Greenblatt DJ, Shader RI, Harmatz JS et al. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. *Am J Psychiatry*. 1977 May;134(5):559-62. PMID [848586 ](https://www.ncbi.nlm.nih.gov/pubmed/?term=848586)
4. Greenblatt DJ, Harmatz JS, Friedman H et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit. 1989b;11(6):652-657. PMID [2512694](https://www.ncbi.nlm.nih.gov/pubmed/?term=2512694)
5. Greenblatt DJ, Divoll M, Harmatz JS et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. *J Pharm Sci*. 1982;71(2):248-252. PMID [6121043](https://www.ncbi.nlm.nih.gov/pubmed/?term=6121043)
6. Gale GD, Galloon S, Porter WR. Sublingual lorazepam: a better premedication? *Br J Anaesth*. 1983 Aug;55(8):761-5. PMID [6136288 ](https://www.ncbi.nlm.nih.gov/pubmed/?term=6136288)
7. Fresenius Kabi. Midazolam USP \[package insert]. U.S. Food and Drug Administration website. Revised \[2017].
8. Pentikäinen PJ, Välisalmi L, Himberg JJ et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. *J Clin Pharmacol*. 1989 Mar;29(3):272-7. PMID [2723115 ](https://www.ncbi.nlm.nih.gov/pubmed/?term=2723115)
9. Phenobarbital Sodium USP \[package insert]. Boucherville, QC, Canada: Sandoz Canada Inc.; 2015
10. Greenblatt DJ, Shader RI, Divoll M et al. Benzodiazepines: a summary of pharmacokinetic properties. *Br J Clin Pharmacol*. 1981;11 Suppl 1:11S-16S. PMID [6133528 ](https://www.ncbi.nlm.nih.gov/pubmed/?term=6133528)
